Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2011

01-07-2011 | Translational Research and Biomarkers

Msi-1 is a Predictor of Survival and a Novel Therapeutic Target in Colon Cancer

Authors: Dawei Li, MD, PhD, Xiao Peng, MD, Dongwang Yan, MD, PhD, Huamei Tang, MD, Fei Huang, MD, Yinxue Yang, MD, PhD, Zhihai Peng, MD, PhD

Published in: Annals of Surgical Oncology | Issue 7/2011

Login to get access

Abstract

Background

Musashi1 (Msi-1), a neural RNA-binding protein, plays an important role in regulating cell differentiation in precursor cells. Recently, aberrant expression of Msi-1 has been detected in several malignancies. However, its role in the progression of colon cancer is largely unknown.

Materials and Methods

We used Western blotting to examine Msi-1 protein expression in 8 cases of primary colon cancer lesions and paired normal colonic mucosa. Msi-1 expression and clinicopathological significance were determined by immunohistochemical staining in a tissue microarray (TMA) containing 203 cases of primary colon cancer paired with noncancerous tissue and 66 lymph node metastasis (LNM) tissues. RNAi was used to analyze the biological function of Msi-1 in vitro.

Results

LNM tissue exhibited a striking increase in Msi-1 expression when compared with primary colon cancer and adjacent normal mucosa (87.9% vs. 64.5% vs. 16.7%, P < .001). Overexpression of Msi-1 was associated with higher clinical stage, T stage, lymph node metastasis, presence of distant metastasis, and Ki-67 positivity. Msi-1 served as an independent prognostic marker whose expression levels correlated with poorer metastasis-free survival (MFS) (HR 5.4; P < .001) and poorer overall survival (OS) (HR 3.8; P < .001). Msi-1 silencing significantly inhibited proliferation ability and attenuated the migration and invasion activity of colon cancer cells.

Conclusions

Our study provides the basis to explore the use of Msi-1 as a novel prognostic biomarker in colon cancer patients. Aberrant overexpression of Msi-1 during metastasis of colon cancer also suggests that it is a potential therapeutic target.
Literature
1.
Wei PL, Chang YJ, Ho YS, Lee CH, Yang YY, An J, et al. Tobacco-specific carcinogen enhances colon cancer cell migration through alpha7-nicotinic acetylcholine receptor. Ann Surg. 2009;249:978–85.PubMedCrossRef
2.
Lawson JC, Blatch GL, Edkins AL. Cancer stem cells in breast cancer and metastasis. Breast Cancer Res Treat. 2009;118:241–54.PubMedCrossRef
3.
Todaro M, Francipane MG, Medema JP, Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology. 2010;138:2151–62.PubMedCrossRef
4.
Okano H, Kawahara H, Toriya M, Nakao K, Shibata S, Imai T. Function of RNA-binding protein Musashi-1 in stem cells. Exp Cell Res. 2005;306:349–56.PubMedCrossRef
5.
Dekaney CM, Rodriguez JM, Graul MC, Henning SJ. Isolation and characterization of a putative intestinal stem cell fraction from mouse jejunum. Gastroenterology. 2005;129:1567–80.PubMedCrossRef
6.
Murayama M, Okamoto R, Tsuchiya K, Akiyama J, Nakamura T, Sakamoto N, et al. Musashi-1 suppresses expression of Paneth cell-specific genes in human intestinal epithelial cells. J Gastroenterol. 2009;44:173–82.PubMedCrossRef
7.
Potten CS, Booth C, Tudor GL, Booth D, Brady G, Hurley P, et al. Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation. 2003;71:28–41.PubMedCrossRef
8.
Kyahara T, Sawada M, Takaishi S, Fukui H, Seno H, Fukuzawa H, et al. Candidate markers for stem and early progenitor cells, Musashi-1 and Hes1, are expressed in crypt base columnar cells of mouse small intestine. FEBS Lett. 2003;535:131–5.CrossRef
9.
10.
Humphries A, Wright NA. Colonic crypt organization and tumorigenesis. Nat Rev Cancer. 2008;8:415–24.PubMedCrossRef
11.
Sureban SM, May R, George RJ, Dieckgraefe BK, McLeod HL, Ramalingam S, et al. Knockdown of RNA binding protein Musashi-1 leads to tumor regression in vivo. Gastroenterology. 2008;134:1448–58.PubMedCrossRef
12.
Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric. Proc Natl Acad Sci USA. 2003;100:15178–83.PubMedCrossRef
13.
Yokota N, Mainprize TG, Taylor MD, Kohata T, Loreto M, Ueda S, et al. Identification of differentially expressed and developmentally regulated genes in using suppression subtraction hybridization. Oncogene. 2004;23:3444–53.PubMedCrossRef
14.
Shu HJ, Saito T, Watanabe H, Ito JI, Takeda H, Okano H, et al. Expression of the Musashi1 gene encoding the RNA-binding protein in human hepatoma cell lines. Biochem Biophys Res Commun. 2002;293:150–4.PubMedCrossRef
15.
Chakravarty D, Nair SS, Santhamma B, Nair BC, Wang L, Bandyopadhyay A, et al. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res. 2010;70:4092–101.PubMedCrossRef
16.
Li D, Yan D, Tang H, Zhou C, Fan J, Li S, et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 2009;16:3499–506.PubMedCrossRef
17.
Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC, et al. Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer. 2006;6:241–51.PubMedCrossRef
18.
Yuqi L, Chengtang W, Ying W, Shangtong L, Kangxiong L. The expression of Msi-1 and its significance in small intestinal mucosa severely damaged by high-dose 5-FU. Dig Dis Sci. 2008;53:2436–42.PubMedCrossRef
19.
Wang XY, Yin Y, Yuan H, Sakamaki T, Okano H, Glazer RI et al. Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways. Mol Cell Biol. 2008;28:3589–99.PubMedCrossRef
20.
Dobson NR, Zhou YX, Flint NC, Armstrong RC. Musashi1 RNA-binding protein regulates oligodendrocyte lineage cell differentiation and survival. Glia. 2008;56:318–30.PubMedCrossRef
21.
Ye F, Zhou C, Cheng Q, Shen J, Chen H. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer. 2008;18:108.CrossRef
22.
Battelli C, Nikopoulos GN, Mitchell JG, Verdi JM. The RNA-binding protein Musashi-1 regulates neural development through the translational repression of p21WAF-1. Mol Cell Neurosci. 2006;31:85–96.PubMedCrossRef
23.
de Sousa Abreu R, Sanchez-Diaz PC, Vogel C, Burns KC, Ko D, Burton TL, et al. Genomic analyses of musashi1 downstream targets show a strong association with cancer-related processes. J Biol Chem. 2009;284:12125–35.PubMedCrossRef
Metadata
Title
Msi-1 is a Predictor of Survival and a Novel Therapeutic Target in Colon Cancer
Authors
Dawei Li, MD, PhD
Xiao Peng, MD
Dongwang Yan, MD, PhD
Huamei Tang, MD
Fei Huang, MD
Yinxue Yang, MD, PhD
Zhihai Peng, MD, PhD
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1567-9

Other articles of this Issue 7/2011

Annals of Surgical Oncology 7/2011 Go to the issue

Colorectal Cancer

OSNA-Based Novel Molecular Testing for Lymph Node Metastases in Colorectal Cancer Patients: Results from a Multicenter Clinical Performance Study in Japan

Translational Research and Biomarkers

Feasibility of ICG Fluorescence-Guided Sentinel Node Biopsy in animal Models using the HyperEye Medical System

Gastrointestinal Oncology

Sentinel Node Navigation Surgery is Acceptable for Clinical T1 and N0 Esophageal Cancer

Translational Research and Biomarkers

Personalizing Thyroid Cancer Care: Are We There Yet?

Translational Research and Biomarkers

Aberrant Expression and Mutation-Inducing Activity of AID in Human Lung Cancer

Translational Research and Biomarkers

Polymorphism in Epidermal Growth Factor Receptor Intron 1 Predicts Prognosis of Patients with Esophageal Cancer after Chemoradiation and Surgery